Exploration of Glutamatergic System With PET Radiotracer in Gilles de la Tourette Patients: Pilot Study (GlutaTour)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-26

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gilles de la Tourette syndrome is a neuropsychiatric disorder characterized by motor and vocal tics often associated with psychiatric comorbidities (obsessive compulsive disorder, anxiety and depressive syndrome, impulsivity). The pathophysiology of Gilles de la Tourette syndrome remains unclear.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 1: Simultaneous PET and 3T MRI

NCT05232955

Gilles de la Tourette Syndrome Tourette Syndrome

COMPLETED

Role of Frontal Cortex in the Pathophysiology of Gilles de la Tourette Syndrome (GTS)

NCT03604510

Tourette Syndrome

COMPLETED NA

Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI

NCT05233306

Gilles de la Tourette Syndrome Tourette Syndrome

COMPLETED

Objective Characterizatoion of Repetitive Behaviors

NCT06050369

OCD Tic Disorders Gilles De La Tourette Syndrome

RECRUITING NA

Neurofeedback for Tourette Syndrome

NCT01702077

Tourette Syndrome Chronic Tic Disorder

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Gilles de la Tourette syndrome is a neuropsychiatric disorder characterized by motor and vocal tics often associated with psychiatric comorbidities (obsessive compulsive disorder, anxiety and depressive syndrome, impulsivity). The pathophysiology of Gilles de la Tourette syndrome remains unclear. It would involve an alteration of striatal-cortico-thalamic cortical circuits resulting in dopaminergic dysfunction. But glutamatergic hypothesis is also discussed from pharmacological, biochemical and genetic arguments. Exploration of glutamatergic system can be done in humans in vivo using a new radiotracer: the \[18F\] FNM (Fluoroethylnormemantine), a derivative of memantine. In the present study, aim of the study 1) to show the glutamatergic system "in vivo" in patients with Tourette's syndrome and 2) to perform correlations between various motor and behavioral symptoms and the pattern of brain fixation for this radiotracer. To do that, a pilot study will be conducted in 12 patients with Tourette's who will be evaluated in terms of motor (tics) and behavioral (OCD, anxiety, depression, impulsivity) symptoms. Each patient will have a PET-scan exam and a brain MRI exam. Data analysis will be carried out from two different approaches: first by region of interest, and secondly, without topographic a priori with the Statistical Parametric Mapping (SPM) software.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tourette Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

compare PET-evaluated glutamaergic system activity (\[18F\]-FNM) between patients with Gilles de la Tourette and healthy volunteers paired in sex, age and manual laterality

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient

patients with Gilles de la Tourette syndrome

Group Type EXPERIMENTAL

Experimental MRI exam and PET scan exam with radiotracer

Intervention Type DIAGNOSTIC_TEST

MRI exam and PET scan exam with radiotracer

Control

healthy control

Group Type EXPERIMENTAL

Experimental MRI exam and PET scan exam with radiotracer

Intervention Type DIAGNOSTIC_TEST

MRI exam and PET scan exam with radiotracer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental MRI exam and PET scan exam with radiotracer

MRI exam and PET scan exam with radiotracer

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Gilles de la Tourette syndrome according to the American Psychiatric association criteria (5 th ed, American Psychiatric association (APA), 2013)
* Aged 18 and over
* Patients treated with 2nd-generation neuroleptics for at least 3months
* Signed consent form

Exclusion Criteria

* contraindications for MRI exam
* claustrophobia
* person under exclusive period for another study
* pregnant women
* patients under non-authorized treatment (1rst generation neuroleptics) or non-treated by neuroleptics

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes